COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
HCQ study #246 of 264
1/26 Safety
Eftekhar et al., medRxiv, doi:10.1101/2021.01.16.21249941 (Preprint)
Hydroxychloroquine and azithromycin: As a double edge sword for COVID-19?
Source   PDF   Share   Tweet
Retrospective 172 hospitalized patients, 83% treated and HCQ+AZ and 17% with HCQ, not finding a significant difference in QTc prolongation, but recommending careful monitoring for the use of HCQ+AZ; especially in males, patients with high-risk Tisdale score, and in patients who have baseline QTc interval ≥ 450 milliseconds.

Eftekhar et al., 1/26/2021, preprint, 6 authors.
Details of all 264 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit